Ajanta Pharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Yogesh Agrawal

Chief executive officer

₹156.3m

Total compensation

CEO salary percentage	71.4%
CEO tenure	16.4yrs
CEO ownership	14.5%
Management average tenure	no data
Board average tenure	13.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Yogesh Agrawal's remuneration changed compared to Ajanta Pharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	₹8b
Dec 31 2023	n/a	n/a	₹7b
Sep 30 2023	n/a	n/a	₹7b
Jun 30 2023	n/a	n/a	₹6b
Mar 31 2023	₹156m	₹112m	₹6b
Dec 31 2022	n/a	n/a	₹6b
Sep 30 2022	n/a	n/a	₹7b
Jun 30 2022	n/a	n/a	₹7b
Mar 31 2022	₹163m	₹94m	₹7b
Dec 31 2021	n/a	n/a	₹7b
Sep 30 2021	n/a	n/a	₹7b
Jun 30 2021	n/a	n/a	₹7b
Mar 31 2021	₹128m	₹75m	₹7b
Dec 31 2020	n/a	n/a	₹6b
Sep 30 2020	n/a	n/a	₹6b
Jun 30 2020	n/a	n/a	₹5b
Mar 31 2020	₹107m	₹66m	₹5b
Dec 31 2019	n/a	n/a	₹4b
Sep 30 2019	n/a	n/a	₹4b
Jun 30 2019	n/a	n/a	₹4b
Mar 31 2019	₹99m	₹61m	₹4b
Dec 31 2018	n/a	n/a	₹4b
Sep 30 2018	n/a	n/a	₹5b
Jun 30 2018	n/a	n/a	₹5b
Mar 31 2018	₹44m	₹13m	₹5b

Compensation vs Market: Yogesh's total compensation ($USD1.87M) is above average for companies of similar size in the Indian market ($USD562.25K).

Compensation vs Earnings: Yogesh's compensation has been consistent with company performance over the past year.

CEO

Yogesh Agrawal (51 yo)

16.4yrs

Tenure

₹156,300,000

Compensation

Mr. Yogesh Mannalal Agrawal, M.B.A, has been Managing Director at Ajanta Pharma Ltd. since December 14, 2007. Mr. Agrawal is handling global business of Ajanta Pharma Ltd.He has handled various aspects of...

Board Members

Name	Position	Tenure	Compensation	Ownership
Yogesh Agrawal	MD & Executive Director	24.1yrs	₹156.30m	14.48% ₹ 43.5b
Rajesh Agrawal	Joint MD & Director	11.1yrs	₹156.30m	14.48% ₹ 43.5b
Madhusudan Agrawal	Executive Vice Chairman of the Board	26.4yrs	₹36.21m	no data
Chandrakant Khetan	Lead Independent Director	15.6yrs	₹1.19m	no data
Ramesh Jhawar	Director of Ajanta Pharma USA Inc.	no data	₹25.50m	no data
Mannalal Agrawal	Chairman of the Board	44.4yrs	₹704.00k	no data
Prabhakar Dalal	Non-Executive Independent Director	9.9yrs	₹833.00k	no data
Viswanathan Kalpati	Non-Executive Independent Director	11.1yrs	₹923.00k	no data
Anjana Grewal	Non-Executive Independent Director	9.9yrs	₹749.00k	no data
Sam Gioskos	Director of Ajanta Pharma Philippines Inc.	no data	no data	no data
Suttian Deerpaul	Director of Ajanta Pharma (Mauritius) Ltd.	no data	no data	no data
Vinayak Muzumdar	Director of Ajanta Pharma (Mauritius) Ltd.	no data	no data	no data

13.3yrs

Average Tenure

71yo

Average Age

Experienced Board: 532331's board of directors are seasoned and experienced ( 13.3 years average tenure).

Ajanta Pharma Management

Management criteria checks 2/4

Key information

Recent management updates

Insider recently sold ₹2.1m worth of stock

Ajanta Pharma Limited, Annual General Meeting, Jul 18, 2023

Insider recently sold ₹1.9m worth of stock

Insufficient new directors

Ajanta Pharma Limited, Annual General Meeting, Aug 04, 2022

Insufficient new directors

Recent updates

Ajanta Pharma Limited (NSEI:AJANTPHARM) announces an Equity Buyback for 1,028,881 shares, representing 0.82% for INR 2,850 million.

Full year 2024 earnings: EPS exceeds analyst expectations

Ajanta Pharma Limited to Report Q4, 2024 Final Results on May 02, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ajanta Pharma Limited Approves Second Interim Dividend for the Year Fiscal Year 2024, Payable on or After 19th February 2024

Ajanta Pharma Limited to Report Q3, 2024 Results on Jan 31, 2024

Second quarter 2024 earnings: EPS exceeds analyst expectations

Ajanta Pharma Limited to Report Q2, 2024 Results on Oct 31, 2023

Price target increased by 10.0% to ₹1,652

First quarter 2024 earnings released: EPS: ₹16.53 (vs ₹13.63 in 1Q 2023)

Ajanta Pharma Limited to Report Q1, 2024 Results on Jul 27, 2023

Insider recently sold ₹2.1m worth of stock

Ajanta Pharma Limited, Annual General Meeting, Jul 18, 2023

Insider recently sold ₹1.9m worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ajanta Pharma Limited to Report Q3, 2023 Results on Feb 01, 2023

Insufficient new directors

Ajanta Pharma Limited Approves Interim Dividend

Second quarter 2023 earnings: EPS misses analyst expectations

Ajanta Pharma Limited to Report Q2, 2023 Results on Nov 03, 2022

Price target increased to ₹1,574

US FDA Announces Inspection of Pharma Limited Dahej Facility

Ajanta Pharma Limited to Report Q1, 2023 Results on Jul 28, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ajanta Pharma Limited, Annual General Meeting, Aug 04, 2022

Price target decreased to ₹2,335

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ajanta Pharma Limited to Report Q4, 2022 Results on May 10, 2022

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ajanta Pharma Limited (NSEI:AJANTPHARM) announces an Equity Buyback for 1,120,000 shares, representing 1.29% for INR 2,856 million.

Insider recently sold ₹8.1m worth of stock

Insider recently sold ₹1.1m worth of stock

Upcoming dividend of ₹9.50 per share

Second quarter 2022 earnings released: EPS ₹22.64 (vs ₹19.51 in 2Q 2021)

Director of Ajanta Pharma USA Inc. recently sold ₹6.9m worth of stock

Price target increased to ₹2,394

First quarter 2022 earnings released: EPS ₹20.08 (vs ₹16.93 in 1Q 2021)

Price target increased to ₹2,260

Price target increased to ₹2,139

Insider recently sold ₹2.1m worth of stock

Full year 2021 earnings released: EPS ₹75.09 (vs ₹53.60 in FY 2020)

Insider recently sold ₹1.9m worth of stock

Full year 2021 earnings released: EPS ₹75.09 (vs ₹53.60 in FY 2020)

New 90-day high: ₹1,831

Insider recently sold ₹14m worth of stock

Revenue and earnings beat expectations

Price target raised to ₹1,857

Third quarter 2021 earnings released: EPS ₹20.41 (vs ₹12.33 in 3Q 2020)

Ajanta Pharma Limited to Report Q3, 2021 Results on Feb 02, 2021

Insider recently sold ₹650k worth of stock

New 90-day high: ₹1,704

Insider recently sold ₹798k worth of stock

Insider recently sold ₹818k worth of stock

New 90-day high: ₹1,678

Insider recently bought ₹3.8m worth of stock

Revenue and earnings beat expectations

Ajanta Pharma Limited to Report Q1, 2021 Results on Jul 30, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age